LMNA messenger RNA expression in highly active antiretroviral therapy-treated HIV-positive patients

Journal of Acquired Immune Deficiency Syndromes

Volumn 46, Issue 4, 2007, Pages 384-389

  Miranda, Merce ^a   Chacón, Matilde R ^a   Vidal, Francesc ^a   Megia, Ana ^a   Richart, Cristóbal ^a,b   Veloso, Sergi ^a   Saumoy, Maria ^a   Olona, Carles ^a   Vendrell, Joan ^a  

^a HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^b Instituto de Salud Carlos III   (Spain)

Author keywords

Highly active antiretroviral therapy; HIV infection; Lipodystrophy; LMNA

Indexed keywords

ANTIRETROVIRUS AGENT; CYTOKINE; EFAVIRENZ; INDINAVIR; ISOPROTEIN; LAMIN A; LAMIN C; LAMIVUDINE; MESSENGER RNA; STAVUDINE;

ABDOMINAL SUBCUTANEOUS FAT; ADIPOGENESIS; ADIPOSE TISSUE; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; CROSS-SECTIONAL STUDY; FEMALE; GENE; GENE EXPRESSION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; HYPOTHESIS; INFLAMMATION; INSULIN RESISTANCE; LIPODYSTROPHY; LMNA GENE; MALE; MARKER GENE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADIPOSE TISSUE; ADULT; ANTHROPOMETRY; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CASE-CONTROL STUDIES; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDIES; CYTOKINES; FEMALE; HIV SEROPOSITIVITY; HUMANS; LAMIN TYPE A; MALE; MIDDLE AGED; REFERENCE VALUES; REGRESSION ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TOMOGRAPHY, X-RAY COMPUTED; VISCERA;

EID: 36049034261     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31815aba1b     Document Type: Article

References (35)

1. Moir RD, Spann TP. The structure and function of nuclear lamins: implications for disease. Cell Mol Life Sci. 2001;58:1748-1757.
2. Lloyd DJ, Trembath RC, Shackleton S. A novel interaction between lamin A and SREBP1: implications for partial lipodystrophy and other laminopathies. Hum Mol Genet. 2002;7:769-777.
3. Shackleton S, Lloyd DJ, Jackson SN, et al. LMNA, encoding lamin A/C, is mutated in partial lipodystrophy. Nat Genet. 2000;24:153-156.
4. Behrens GM, Lloyd D, Schmidt HH, et al. Lessons from lipodystrophy: LMNA, encoding lamin A/C, in HIV therapy-associated lipodystrophy. AIDS. 2000;14:1854-1855.
5. Behrens GM, Genschel J, Schmidt RE, et al. Lack of mutations in LMNA, its promoter region, and the cellular retinoic acid binding protein II (CRABP II) in HIV associated lipodystrophy. Eur J Med Res. 2003;8:221-225.
6. Domingo P, Baiget M, Arroyo JA, et al. Absence of mutations in exon 8 of the gene in combination antiretroviral therapy-associated partial lipodystrophy. J Acquir Immune Defic Syndr. 2002;30:457-458.
7. Behrens GM, Stoll M, Schmidt RE. Lipodystrophy syndrome in HIV infection: what is it, what causes it and how can it be managed? Drug Saf. 2000;23:57-76.
8. Caron M, Auclair M, Sterlingot H, et al. Some HIV protease inhibitors alter lamin A/C maturation and stability, SREBP-1 nuclear localization and adipocyte differentiation. AIDS. 2003;17:2437-2444.
9. Kudlow BA, Jameson SA, Kennedy BK. HIV protease inhibitors block adipocyte differentiation independently of lamin A/C. AIDS. 2005;19:1565-1573.
10. Garg A, Vinaitheerthan M,Weatherall P, et al. Phenotypic heterogeneity in patients with familial partial lipodystrophy (Dunnigan variety) related to the site of mis-sense mutations in lamin A/C (LMNA) gene. J Clin Endocrinol Metab. 2001;86:59-65.
11. Young J, Morbois-Trabut L, Couzinet B, et al. Type A insulin resistance syndrome revealing a novel lamin A mutation. Diabetes. 2005;54:1873-1878.
12. Fong LG, Ng JK, Lammerding J, et al. Prelamin A and lamin A appear to be dispensable in the nuclear lamina. J Clin Invest. 2006;116:743-752.
13. Lelliott CJ, Logie L, Sewter CP, et al. Lamin expression in human adipose cells in relation to anatomical site and differentiation state. J Clin Endocrinol Metab. 2002;87:728-734.
14. Machiels BM, Broers JLV, Raymond Y, et al. Abnormal A-type lamin organisation in a human lung carcinoma cell line. Eur J Cell Biol. 1995;67:328-335.
15. Machiels BM, Ramaekers FC, Kuijpers HJ, et al. Nuclear lamin expression in normal testis and testicular germ cell tumours of adolescents and adults. J Pathol. 1997;182:197-204.
16. Carr A, Samaras K, Thorisdottir A, et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet. 1999;353:2093-2099.
17. Fernandez-Real JM, Broch M, RicartW, et al. Plasma levels of the soluble fraction of tumor necrosis factor receptor 2 and insulin resistance. Diabetes. 1998;47:1757-1762.
18. Vigouroux C, Auclair M, Dubosclard E, et al. Nuclear envelope disorganization in fibroblasts from lipodystrophic patients with heterozygous R482Q/W mutations in the lamin A/C gene. J Cell Sci. 2001;114:4459-4468.
19. Capanni C, Cenni V, Mattioli E, et al. Failure of lamin A/C to functionally assemble in R482L mutated familial partial lipodystrophy fibroblasts: altered intermolecular interaction with emerin and implications for gene transcription. Exp Cell Res. 2003;291:122-134.
20. Broers JL, Kuijpers HJ, Ostlund C, et al. Both lamin A and lamin C mutations cause lamina instability as well as loss of internal nuclear lamin organization. Exp Cell Res. 2005;304:582-592.
21. Raharjo WH, Enarson P, Sullivan T, et al. Nuclear envelope defects associated with LMNA mutations cause dilated cardiomyopathy and Emery-Dreifuss muscular dystrophy. J Cell Sci. 2001;114:4447-4457.
22. Holt I, Clements L, Manilal S, et al. The R482Q lamin A/C mutation that causes lipodystrophy does not prevent nuclear targeting of lamin A in adipocytes or its interaction with emerin. Eur J Hum Genet. 2001;9:204-208.
23. Östlund C, Bonne G, Schwartz K, et al. Properties of lamin A mutants found in Emery-Dreifuss muscular dystrophy, cardiomyopathy and Dunnigan-type partial lipodystrophy. J Cell Sci. 2001;114:4435-4445.
24. Murase Y, Yagi K, Katsuda Y, et al. An LMNA variant is associated with dyslipidemia and insulin resistance in the Japanese. Metabolism. 2002;51:1017-1021.
25. Owen KR, Groves CJ, Hanson RL, et al. Common variation in the LMNA gene (encoding lamin A/C) and type 2 diabetes: association analyses in 9,518 subjects. Diabetes. 2007;56:879-883.
26. Wolford JK, Hanson RL, Bogardus C, et al. Analysis of the lamin A/C gene as a candidate for type II diabetes susceptibility in Pima Indians. Diabetologia. 2001;44:779-782.
27. Yiannakouris N, Melistas L, Kontogianni M, et al. The Val81 missense mutation of the melanocortin 3 receptor gene, but not the 1908c/T nucleotide polymorphism in lamin A/C gene, is associated with hyperleptinemia and hyperinsulinemia in obese Greek Caucasians. J Endocrinol Invest. 2004;27:714-720.
28. Mesa JL, Loos RJ, Franks PW, et al. Lamin A/C polymorphisms, type 2 diabetes, and the metabolic syndrome: case-control and quantitative trait studies. Diabetes. 2007;56:884-889.
29. Lammerding J, Schulze PC, Takahashi T, et al. Lamin A/C deficiency causes defective nuclear mechanics and mechanotransduction. J Clin Invest. 2004;113:370-378.
30. Equils O, Faure E, Thomas L, et al. Bacterial lipopolysaccharide activates HIV long terminal repeat through Toll-like receptor 4. J Immunol. 2001;166:2342-2347.
31. Decrion AZ, Dichamp I, Varin A, et al. HIV and inflammation. Current HIV Research. 2005;3:243-259.
32. Lenhard JM, Furfine ES, Jain RG, et al. HIV protease inhibitors block adipogenesis and increase lipolysis in vitro. Antiviral Res. 2000;47:121-129.
33. Okumura K, Nakamachi K, Hosoe Y, et al. Identification of a novel retinoic acid-responsive element within the lamin A/C promoter. Biochem Biophys Res Commun. 2000;269:197-202.
34. Eriksson M, Brown WT, Gordon LB, et al. Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. Nature. 2003;423:293-298.
35. Scaffidi P, Misteli T. Lamin A-dependent nuclear defects in human aging. Science. 2006;312:1059-1063.